Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker Sells 38,547 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the transaction, the vice president now owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. This trade represents a 41.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regulus Therapeutics Trading Up 3.7 %

RGLS stock opened at $1.27 on Thursday. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79. The firm has a 50 day moving average of $1.52 and a 200 day moving average of $1.59.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Creative Planning acquired a new stake in shares of Regulus Therapeutics during the third quarter worth about $26,000. SG Americas Securities LLC purchased a new position in Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Jane Street Group LLC acquired a new stake in Regulus Therapeutics during the 3rd quarter valued at approximately $46,000. JPMorgan Chase & Co. boosted its holdings in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Regulus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.